GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CanBas Co Ltd (TSE:4575) » Definitions » Debt-to-EBITDA

CanBas Co (TSE:4575) Debt-to-EBITDA : 0.00 (As of Dec. 2023)


View and export this data going back to 2009. Start your Free Trial

What is CanBas Co Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

CanBas Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was 円0.00 Mil. CanBas Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was 円0.00 Mil. CanBas Co's annualized EBITDA for the quarter that ended in Dec. 2023 was 円-795.37 Mil. CanBas Co's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was 0.00.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for CanBas Co's Debt-to-EBITDA or its related term are showing as below:

TSE:4575's Debt-to-EBITDA is not ranked *
in the Biotechnology industry.
Industry Median: 1.36
* Ranked among companies with meaningful Debt-to-EBITDA only.

CanBas Co Debt-to-EBITDA Historical Data

The historical data trend for CanBas Co's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CanBas Co Debt-to-EBITDA Chart

CanBas Co Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only - -1.32 -1.44 -0.43 -

CanBas Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of CanBas Co's Debt-to-EBITDA

For the Biotechnology subindustry, CanBas Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CanBas Co's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CanBas Co's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where CanBas Co's Debt-to-EBITDA falls into.



CanBas Co Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

CanBas Co's Debt-to-EBITDA for the fiscal year that ended in Jun. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 0) / -1241.689
=0.00

CanBas Co's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 0) / -795.372
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.


CanBas Co  (TSE:4575) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


CanBas Co Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of CanBas Co's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


CanBas Co (TSE:4575) Business Description

Traded in Other Exchanges
N/A
Address
9 Toriyoko-cho, Shizuoka, JPN, 410-0891
CanBas Co Ltd focuses on the discovery and development of novel oncology drugs targeting the cell cycle. Its product, CBP501 the anticancer drug candidate is a modified synthetic peptide which enhances the efficacy of cisplatin without adding toxicity.

CanBas Co (TSE:4575) Headlines

No Headlines